Q32 Bio to take Homology Medicines’ Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions

The re­verse merg­ers are flow­ing. Q32 Bio will take Ho­mol­o­gy Med­i­cines’ place on the Nas­daq, the com­pa­nies said Thurs­day morn­ing, and the bi­o­log­ics mak­er ex­pects to have about $115 mil­lion at the time their deal clos­es, like­ly in the first quar­ter of 2024.

The Mass­a­chu­setts biotechs fol­low Lenz Ther­a­peu­tics and Graphite Bio in join­ing the re­verse merg­er train, which, by year’s end, is ex­pect­ed to board a few more pri­vate com­pa­nies look­ing to take the pub­lic list­ing and cash of a biotech that flamed out in the clin­ic or re­sort­ed to “strate­gic al­ter­na­tives” for some oth­er rea­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.